A randomized, placebo-controlled, phase I/II trial of the anti-HIV activity and safety of VGX-410 (mifepristone) at three dose levels in HIV-1 infected subjects.

Trial Profile

A randomized, placebo-controlled, phase I/II trial of the anti-HIV activity and safety of VGX-410 (mifepristone) at three dose levels in HIV-1 infected subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2012

At a glance

  • Drugs Mifepristone (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2010 Results were published in the Journal of Acquired Immune Deficiency Syndromes.
    • 28 Sep 2008 Actual end date (May 2007) added as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top